Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Leaf cutter ants inspire new anti-cancer drugs

By R&D Editors | July 3, 2013

Scientists at the Univ. of East Anglia (UEA) are developing a new class of anti-cancer drugs that are not only powerful but also circumvent a primary cause of resistance to chemotherapy. The work is inspired by nature’s fungus farmer, the leaf cutter ant.

Matt Hutchings, lead researcher, and his team have been studying a type of antibiotic that is produced by bacteria that live in symbiosis with leaf cutter ants. They have identified the genetic pathway involved in producing the antibiotic, opening the possibility to use this natural product as the basis for new drugs, including anti-cancer treatments.

The Streptomyces bacteria live on the outer surface of the ants, providing antibiotic protection against disease-causing infection. Among the antibiotics they produce are compounds called antimycins which have powerful activity against drug resistant cancer cells. Over 40 members of the antimycin family of antibiotics are known but the pathway was only recently identified by the UEA research team.

Hutchings, from UEA’s School of Biological Sciences, said: “We’re using genetics to understand how the drugs are made in the bacteria so we can tweak the characteristics in favor of anti-cancer action, whilst protecting healthy cells. We want to make Streptomyces into a factory to produce a new type of chemotherapy drug on a large scale.

“What’s particularly exciting is that the way the drugs work actually tackles one of the main causes of resistance to chemotherapy. In fact, the harder the cancer cell tries to overcome the chemotherapy, the more effective the drug is!”

Resistance to chemotherapy often arises because cancer cells produce proteins that prevent apoptosis, or ‘cell suicide’, that would otherwise be triggered by the treatment. But antimycins actually inhibit the action of these proteins, allowing apoptosis to continue unhindered.

Hutchings said: “Although scientists have known about these antibiotics for more than 60 years, we’ve only recently identified two genetic pathways that are involved in making these molecules and we’re looking for still more.”

Work by organic chemists has shown that antimycins can be altered to inhibit their harmful characteristics and promote the useful ones. Specifically, they can be very toxic to all cells because they interfere with fundamental metabolic processes, but it’s possible to dramatically reduce this effect by altering their chemistry.

Hutchings’ team aims to make these changes through genetics so that the drugs can be made cheaply and on a large scale using bacteria in fermentation tanks.

Source: Univ. of East Anglia

Related Articles Read More >

Argonne webinar to explore the challenges of recycling lithium-ion batteries and solutions
U.S. DOE grants $25M to advance clean hydrogen technologies for electricity generation 
Advanced Ionics secures $4.2M for decarbonization of industrial hydrogen production
MilliporeSigma’s ZooMAb antibodies earns first-ever ACT Label from My Green Lab
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars